CoChat

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

Open access
Kocik, Justyna, Machula, Monika, Wisniewska, Aneta, Surmiak, Ewa, Holak, Tad A., Skalniak, Lukasz · 2019 · Cancers

The DOI matches its Crossref record; 236 of the 237 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

The protein p53, known as the “Guardian of the Genome”, plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions in the TP53 gene. In the remaining 50% of cases the overexpression of HDM2 (mouse double minute 2, human homolog) protein, which is a natural inhibitor of p53, is the most common way of keeping p53 inactive. Disruption of HDM2-p53 interaction with the use of HDM2 antagonists leads to the release of p53 and expression of its target genes, engaged in the induction of cell cycle arrest, DNA repair, senescence, and apoptosis. The induction of apoptosis, however, is restricted to only a handful of p53wt cells, and, generally, cancer cells treated with HDM2 antagonists are not efficiently eliminated. For this reason, HDM2 antagonists were tested in combinations with multiple other therapeutics in a search for synergy that would enhance the cancer eradication. This manuscript aims at reviewing the recent progress in developing strategies of combined cancer treatment with the use of HDM2 antagonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11071014

Cites

236 of 237 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The outline of the main strategies of supporting the action of HDM2 (mouse double minute2, Mdm2, human homolog) antagonists in the recent experimental combination therapies.
Figure 1 The outline of the main strategies of supporting the action of HDM2 (mouse double minute2, Mdm2, human homolog) antagonists in the recent experimental combination therapies.CC BY · PubMed Central
Figure 2 Structures of the potent HDM2 antagonists used in combination therapies. Binding of the compounds with protein HDM2 subpockets based on crystal structure or predicted is color labeled: Trp23—blue; Phe19—red; Leu26—green.
Figure 2 Structures of the potent HDM2 antagonists used in combination therapies. Binding of the compounds with protein HDM2 subpockets based on crystal structure or predicted is color labeled: Trp23—blue; Phe19—red; Leu26—green.CC BY · PubMed Central
Figure 3 The outline of the combinations of HDM2 antagonists with DNA-damaging agents and the drugs that sustain DNA damage response.
Figure 3 The outline of the combinations of HDM2 antagonists with DNA-damaging agents and the drugs that sustain DNA damage response.CC BY · PubMed Central
Figure 4 The outline of the combinations of HDM2 antagonists with apoptosis-inducing agents.
Figure 4 The outline of the combinations of HDM2 antagonists with apoptosis-inducing agents.CC BY · PubMed Central
Figure 5 The outline of the combinations of HDM2 antagonists with targeted therapy agents.
Figure 5 The outline of the combinations of HDM2 antagonists with targeted therapy agents.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 237 references

Cited by

See all 49

Metadata

Authors
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L.
Affiliations
  • Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30–387 Krakow, Poland
  • Jagiellonian University (PL)
Venue
Cancers
Publisher
MDPI AG
Published
2019-07-19
Volume
11
Issue
7
Pages
1014
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2963228228
Cited by
46
References
237
Citations by year
2026: 2 · 2025: 7 · 2024: 11 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 8
FWCI
0.48
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Narodowe Centrum Nauki (UMO-2016/21/D/NZ7/00596)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
p53, MDM2, combination therapy, anticancer activity, apoptosis, TP53 mutation, synergistic effect, cancer therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. https://app.cochat.ai/papers/10.3390/cancers11071014
The paper
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019). Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers. https://doi.org/10.3390/cancers11071014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.